Latest Anticonvulsants Stories
DALLAS, March 4, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Epilepsy - Pipeline Review, H1 2015" therapeutic market research report of 330 pages with latest updates,
WOODCLIFF LAKE, N.J., Feb.
Free Trial Offer, Co-Pay Program and Prior Authorization Assistance Now Available MAPLE GROVE, Minn., Feb.
- Major milestone for brivaracetam is latest step towards UCB goal of extending treatment choices for adult epilepsy patients with uncontrolled partial-onset seizures BRUSSELS, Jan.
Multiple Presentations Highlight Long-Term Safety, Tolerability, and Efficacy Measures, as Adjunctive Therapy for Patients with Refractory Partial-Onset Seizures SEATTLE, Dec.
-- Primary efficacy and safety data from the largest Phase 3 brivaracetam study involving 768 patients presented at the 68th Annual Meeting of the American Epilepsy Society BRUSSELS, Dec.
-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters -- WOODCLIFF LAKE, N.J., Dec. 5, 2014 /PRNewswire/ -- Eisai Inc.
- 24 UCB-sponsored presentations including new data on VIMPAT® (lacosamide) BRUSSELS, Dec.
Global Epilepsy Market 2014-2018 profiles key players like GlaxoSmithKline plc, Pfizer Inc. and UCB SA.
Findings Presented at 43rd Annual Meeting of the Child Neurology Society MAPLE GROVE, Minn., Oct.
- The act of lurking; skulking about; hiding; keeping from sight.